172P Updated analysis: observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin (OX) + BV and oral FU/OX + BV
Yoshito Komatsu, Satoshi Yuki, Hiroshi Nakatsumi, Kentaro Sawada, Kazuteru Hatanaka, Takashi Kato, T. Meguro, Michio Nakamura, Ichiro Iwanaga, Minoru Uebayashi, M. Tateyama, K. Eto, Masatoshi Kudo, K. Kato, Hiroyuki Okuda, Susumu Sogabe, T. Miyagishima, Kencho Miyashita, Naoya Sakamoto, Yuh Sakata (2015). 172P Updated analysis: observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin (OX) + BV and oral FU/OX + BV. , 26, DOI: https://doi.org/10.1093/annonc/mdv523.33.
